These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7044051)

  • 1. Single versus multiple daily administration of hydralazine in the maintenance treatment of hypertension. Clinical and pharmacokinetic aspects.
    Henningsen NC; Hanson A; Wernersson B
    Acta Med Scand; 1982 May; 211(3):179-85. PubMed ID: 7044051
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of alprenolol in combination with hydralazine in essential hypertension. A double-blind, crossover study and a long-term follow-up study.
    Pape J
    Acta Med Scand Suppl; 1974; 554():55-62. PubMed ID: 4593674
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of once daily hydralazine in inadequately controlled hypertension.
    Danielson M; Kjellberg J; Ohman P; Wernersson B
    Acta Med Scand; 1983; 214(5):373-80. PubMed ID: 6362341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydralazine and beta-adrenergic blockade in the treatment of hypertension.
    Siitonen L; Jänne J; Keyriläinen O; Koskinen P; Leskinen O; Pitkäjärvi T; Reinikainen M
    Ann Clin Res; 1974 Dec; 6(6):341-6. PubMed ID: 4155933
    [No Abstract]   [Full Text] [Related]  

  • 5. Hydralazine once daily in hypertension.
    Silas JH; Ramsay LE; Freestone S
    Br Med J (Clin Res Ed); 1982 May; 284(6329):1602-4. PubMed ID: 6805621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of timolol plus hydrochlorothiazide plus hydralazine on essential hypertension.
    Aronow WS; Van Herick R; Greenfield R; Alimadadian H; Burwell D; Mann W
    Circulation; 1978 May; 57(5):1017-21. PubMed ID: 346252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydralazine and prazosin in the treatment of hypertension.
    Vandenburg MJ; Sharman VL; Wright P; Drew PJ; Barnes JN
    Br J Clin Pharmacol; 1983 Nov; 16(5):537-42. PubMed ID: 6357257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of hydralazine, in conventional and slow-release preparations, during long-term treatment of primary hypertension.
    Lins LE; Berglund J; Eliasson K; Wernersson B
    Clin Ther; 1983; 5(3):251-9. PubMed ID: 6850719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of hydralazine action in hypertension.
    O'Malley K; Segal JL; Israili ZH; Boles M; McNay JL; Dayton PG
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):581-6. PubMed ID: 1102235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Slow-release hydralazine in the treatment of essential arterial hypertension].
    Moscovici H; Yasbeck Júnior P; Fadul Neto J
    Arq Bras Cardiol; 1982 Sep; 39(3):197-9. PubMed ID: 7186366
    [No Abstract]   [Full Text] [Related]  

  • 11. Propranolol-hydralazine combination in essential hypertension.
    Stevens JD; Binstok G; Mullane JF; Woods JW; Pittman AW; del Greco F; Huang C; Morledge JH
    Clin Ther; 1983; 5(5):525-39. PubMed ID: 6352036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reserpine, hydralazine, hydrochlorothiazide combination (Ser-AP-ES) in essential hypertension.
    Glazer N
    Curr Ther Res Clin Exp; 1972 Sep; 14(9):561-72. PubMed ID: 4628678
    [No Abstract]   [Full Text] [Related]  

  • 13. Kinetics of hydralazine and its main metabolites in slow and fast acetylators.
    Reece PA; Cozamanis I; Zacest R
    Clin Pharmacol Ther; 1980 Dec; 28(6):769-78. PubMed ID: 7438692
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of oral dose size on hydralazine kinetics and vasodepressor response.
    Shepherd AM; Irvine NA; Ludden TM; Lin MS; McNay JL
    Clin Pharmacol Ther; 1984 Nov; 36(5):595-600. PubMed ID: 6488679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hydralazine in arterial hypertension. Randomized, double-blind comparison between conventional and slow-release preparations].
    Wulff K; Lenz K; Krogsgaard AR; Holst B
    Ugeskr Laeger; 1980 Jul; 142(29):1862-5. PubMed ID: 6996259
    [No Abstract]   [Full Text] [Related]  

  • 16. Hydralazine slow-release: observations on serum profile and clinical efficacy in man.
    Talseth T; Fauchald P; Pape JF
    Curr Ther Res Clin Exp; 1977 Feb; 21(2):157-68. PubMed ID: 403050
    [No Abstract]   [Full Text] [Related]  

  • 17. A double-blind, randomized, controlled trial comparing pinacidil to hydralazine in essential hypertension.
    Byyny RL; Nies AS; LoVerde ME; Mitchell WD
    Clin Pharmacol Ther; 1987 Jul; 42(1):50-7. PubMed ID: 3297468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of response to intravenous hydralazine in hypertension.
    Shepherd A; Lin MS; McNay J; Ludden T; Musgrave G
    Clin Pharmacol Ther; 1981 Dec; 30(6):773-81. PubMed ID: 7307426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety comparison of nitrendipine and hydralazine as antihypertensive monotherapy.
    Fagan TC; Sternleib C; Vlachakis N; Deedwania PC; Mehta JL
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1109-13. PubMed ID: 6085377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients.
    Gaynor MF; Wright GC; Vondracek S
    Ther Adv Cardiovasc Dis; 2018 Jan; 12(1):7-15. PubMed ID: 29265003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.